Genomic signature and toxicogenomics comparison of polycationic gene delivery nanosystems in human alveolar epithelial A549 cells

Daru

Volumn 17, Issue 3, 2009, Pages 139-147

  Barar, J ^a   Hamzeiy, H ^b   Mortazavi Tabatabaei, S A ^a   Hashemi Aghdam, S E ^a   Omidi, Y ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Gene delivery nanosystem; Gene expression; Genocompatibility; Microarray; Toxicogenomics

Indexed keywords

COMPLEMENTARY DNA; DENDRIMER; DIAMINOBUTANE DENDRIMER; NANOMATERIAL; OLIGOFECTAMINE; POLYAMIDOAMINE; POLYFECT; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; GENE EXPRESSION; GENE TARGETING; GENOTOXICITY; LUNG ALVEOLUS CELL; LUNG ALVEOLUS EPITHELIUM; MICROARRAY ANALYSIS; NANOTECHNOLOGY; NUCLEOTIDE SEQUENCE;

EID: 70350336452     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Akhtar S, Benter I. (2007) Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv.Drug Deliv.Rev., 59, 164-182. (Pubitemid 46773052)
2. Niidome T, Huang L. (2002) Gene therapy progress and prospects: nonviral vectors. Gene Ther, 9, 1647-1652 (Pubitemid 36104607)
3. Ferber D. (2001) Gene therapy. Safer and virus-free? Science, 294, 1638-1642
4. Panyam J, Labhasetwar V. (2003) Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev, 55, 329-347 (Pubitemid 36297053)
5. Somia N, Verma IM. (2000) Gene therapy: trials and tribulations. Nat Rev Genet, 1, 91-99.
6. Forrest ML, Pack DW. (2002) On the kinetics of polyplex endocytic trafficking: implications for gene delivery vector design. Mol Ther, 6, 57-66.
7. Pedroso de Lima MC, Simoes S, Pires P, Faneca H, Duzgunes N. (2001) Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications. Adv Drug Deliv Rev, 47, 277-294 (Pubitemid 32324118)
8. Medina-Kauwe LK, Xie J, Hamm-Alvarez S. (2005) Intracellular trafficking of nonviral vectors. Gene Ther., 12, 1734-1751.
9. Omidi Y, Hollins AJ, Benboubetra M, Drayton R, Benter IF, Akhtar S. (2003) Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin- and oligofectamine-induced gene expression changes in human epithelial cells. J Drug Target, 11, 311-323 (Pubitemid 38081335)
10. Hollins AJ, Omidi Y, Benter IF, Akhtar S. (2007) Toxicogenomics of drug delivery systems: Exploiting delivery system-induced changes in target gene expression to enhance siRNA activity. J.Drug Target, 15, 83-88. (Pubitemid 47161335)
11. Omidi Y, Hollins AJ, Drayton RM, Akhtar S. (2005) Polypropylenimine dendrimer-induced gene expression changes: the effect of complexation with DNA, dendrimer generation and cell type. J.Drug Target, 13, 431-443. (Pubitemid 43084544)
12. Omidi Y, Barar J, Akhtar S. (2005) Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray technology. Curr.Drug Deliv., 2, 429-441. (Pubitemid 41277775)
13. Omidi Y, Barar J, Heidari HR, Ahmadian S, Ahmadpour Yazdi H, Akhtar S. (2008) Microarray Analysis of the Toxicogenomics and the Genotoxic Potential of a Cationic Lipid-Based Gene Delivery Nanosystem in Human Alveolar Epithelial A549 Cells. Toxicology Mechanisms and Methods, 18, 369-378. (Pubitemid 351892732)
14. Hosack DA, Dennis G, Jr., Sherman BT, Lane HC, Lempicki RA. (2003) Identifying biological themes within lists of genes with EASE. Genome Biol, 4, R70.
15. Ilies MA, Seitz WA, Balaban AT. (2002) Cationic lipids in gene delivery: principles, vector design and therapeutical applications. Curr.Pharm.Des, 8, 2441-2473.
16. Zuhorn IS, Engberts JB, Hoekstra D. (2007) Gene delivery by cationic lipid vectors: overcoming cellular barriers. Eur.Biophys.J., 36, 349-362. (Pubitemid 46626209)
17. Boulaiz H, Marchal JA, Prados J, Melguizo C, Aranega A. (2005) Non-viral and viral vectors for gene therapy. Cell Mol.Biol., 51, 3-22. (Pubitemid 43093388)
18. Li SD, Huang L. (2006) Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Ther., 13, 1313-1319.
19. Filion MC, Phillips NC. (1997) Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta, 1329, 345-356
20. Pedroso de Lima MC, Neves S, Filipe A, Duzgunes N, Simoes S. (2003) Cationic liposomes for gene delivery: from biophysics to biological applications. Curr Med Chem, 10, 1221-1231 (Pubitemid 36763932)
21. Mahato RI, Takakura Y, Hashida M. (1997) Nonviral vectors for in vivo gene delivery: physicochemical and pharmacokinetic considerations. Crit Rev Ther Drug Carrier Syst, 14, 133-172 (Pubitemid 27169245)
22. Schreier H, Gagne L, Bock T, Erdos GW, Druzgala P, Conary JT, Muller BW. (1997) Physicochemical properties and in vitro toxicity of cationic liposome cDNA complexes. Pharm Acta Helv, 72, 215-223 (Pubitemid 27455813)
23. Takakura Y, Nishikawa M, Yamashita F, Hashida M. (2002) Influence of physicochemical properties on pharmacokinetics of non-viral vectors for gene delivery. J Drug Target, 10, 99-104. (Pubitemid 34272377)
24. Tabatt K, Sameti M, Olbrich C, Muller RH, Lehr CM. (2004) Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer. Eur.J.Pharm.Biopharm., 57, 155-162. (Pubitemid 38283690)
25. Tan Y, Huang L. (2002) Overcoming the inflammatory toxicity of cationic gene vectors. J Drug Target, 10, 153-160 (Pubitemid 34272383)
26. Gebhart CL, Kabanov AV. (2001) Evaluation of polyplexes as gene transfer agents. J Control Release, 73, 401-416 (Pubitemid 32539266)
27. Gaga M, Zervas E, Grivas S, Castro M, Chanez P. (2007) Evaluation and management of severe asthma. Curr.Med Chem., 14, 1049-1059.
28. Behrens P, Brinkmann U, Wellmann A. (2003) CSE1L/CAS: its role in proliferation and apoptosis. Apoptosis., 8, 39-44. (Pubitemid 36133136)
29. Hammer M, Mages J, Dietrich H, Servatius A, Howells N, Cato AC, Lang R. (2006) Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock. J.Exp.Med. , 203, 15-20. (Pubitemid 43139639)
30. Devi AR, Gopikrishna M, Ratheesh R, Savithri G, Swarnalata G, Bashyam M. (2006) Farber lipogranulomatosis: clinical and molecular genetic analysis reveals a novel mutation in an Indian family. J.Hum.Genet., 51, 811-814. (Pubitemid 44386826)
31. Hong TM, Yang PC, Peck K, Chen JJ, Yang SC, Chen YC, Wu CW. (2000) Profiling the downstream genes of tumor suppressor PTEN in lung cancer cells by complementary DNA microarray. Am.J.Respir. Cell Mol.Biol., 23, 355-363. (Pubitemid 30701846)
32. Schultz DR, Harrington WJ, Jr. (2003) Apoptosis: programmed cell death at a molecular level. Semin. Arthritis Rheum., 32, 345-369.
33. Peruzzi B, Bottaro DP. (2006) Targeting the c-Met signaling pathway in cancer. Clin.Cancer Res., 12, 3657-3660. (Pubitemid 44000247)
34. Serizawa H, Makela TP, Conaway JW, Conaway RC, Weinberg RA, Young RA. (1995) Association of Cdk-activating kinase subunits with transcription factor TFIIH. Nature, 374, 280-282.
35. Haziot A, Lin XY, Zhang F, Goyert SM. (1998) The induction of acute phase proteins by lipopolysaccharide uses a novel pathway that is CD14-independent. J.Immunol., 160, 2570-2572. (Pubitemid 28136705)
36. Xu M, Sheppard KA, Peng CY, Yee AS, Piwnica-Worms H. (1994) Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Mol.Cell Biol., 14, 8420-8431.
37. Pusztai L, Krishnamurti S, Perez CJ, Sneige N, Esteva FJ, Volchenok M, Breitenfelder P, Kau SW, Takayama S, Krajewski S, Reed JC, Bast RC, Jr., Hortobagyi GN. (2004) Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer. Cancer Invest, 22, 248-256. (Pubitemid 38725179)
38. Omidi Y, Barar J. (2009) Induction of human alveolar epithelial cell growth factor receptors by dendrimeric nanostructures. Int.J.Toxicol., 28, 113-122.